By integrating transcriptomic, human AD brain, genomic, and Mendelian randomization analyses, we identified the lipid‐modifying enzyme LPCAT2 as a sex‐ and APOE genotype–dependent causal mediator of both heightened pain vulnerability and AD progression. This evidence concerns the gene LPCAT2 and Alzheimer disease.